Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Participant is ≥18 years of age at the time of informed consent.~2. Participant has AHA, and is being treated/was treated with Obizur.~3. Participant or the participant's legally authorized representative is willing and able to provide informed consent, unless informed consent is not required~Exclusion Criteria:~1. Participant has a known anaphylactic reaction to the active substance, to any of the excipients, or to hamster protein.~2. Participant has a concomitant bleeding disorder(s) other than acquired hemophilia A (AHA).~3. Participant has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBIZUR - Prospective Participants (Type: None): Participants enrolled and treated with Obizur after the prospective study start date
- OBIZUR - Retrospective Participants (Type: None): Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date

Based on this trial design, predict the completion outcome and termination type (if applicable).